Biography

Klauss Villalva-Serra, MD, is a physician and researcher specializing in tuberculosis epidemiology and public health. He earned his medical degree from the University of Salvador, Brazil, and currently works as a data analyst for RePORT-Brazil and as a researcher at the Laboratory of Clinical and Translational Medicine, Oswaldo Cruz Foundation. His work focuses on the application of advanced data analysis and modelling strategies to improve TB prevention. With multiple publications in high-tier journals and international research experiences, Klauss is committed to evidence-based innovation that informs policy and drives impactful solutions in global TB care.

Expertise

TB Diagnostics
Public Health

Key Impacts

Cost-effectiveness of replacing 6-9H isoniazid monotherapy with 3HP for TB preventive therapy in Brazil: A national and sub-national analysis

Transitioning from traditional isoniazid monotherapy (6-9H) to the shorter 3HP regimen would improve treatment completion rates, while also offering substantial economic savings and reductions in TB-burden across Brazil. This cost-effective strategy presents an impactful opportunity for national and state health policymakers to optimize limited resources, accelerate progress toward TB elimination, and alleviate economic strain on healthcare systems.

Source: Conference 2024